Olivier Rixe, M.D., Ph.D. Professor Section of Hematology/Oncology Director, Experimental Therapeutics Program Leader, Neuro-Oncology Program
Date: December 11, 2012 Time: Noon-1:00 PM Location: BC-140 Title of Presentation: "Is there a future role for antiangiogenics in oncology? The $440 Billion Question…“
About the Speaker: Olivier Rixe, MD, PhD, is an internationally recognized medical oncologist in the field of developmental therapeutics. Dr. Rixe has received numerous awards, including the prestigious Merit Order (Ordre National du Merite) for cancer research from the President of France, Jacques Chirac.
Dr. Rixe has published approximately 150 publications in peer-reviewed journals. In academia he has held senior positions for the past 15 years conducting clinical trials in patients with resistant tumors. His research includes many translational studies. Active in numerous drug trials, Dr. Rixe has been involved in the early phases of development for the U.S. Food and Drug Administration (FDA) approved agents, such as oxaliplatin, camptothecins, and taxanes, as well as targeted therapies including the antiangiogenic compounds sunitinib, axitinib and VEGF-trap.
Dr. Rixe received his medical degree from the Pierre and Marie Curie University of Paris, France in 1993, and completed four years of training in medical oncology and internal medicine in Paris. At the National Institutes of Health National Cancer Institute's (NCI) Medical Oncology Branch in Bethesda, Maryland he conducted one- year of laboratory research (1991-92). Dr. Rixe receivedhis Ph.D. in molecular biology at Paris Diderot University, France in 2002.
He served as a senior medical oncologist at the renowned Pitie-Salpêtrière Hospital in Paris, and subsequently in the Phase 1 Unit at Gustave Roussy Institute in Villejuif, France. In 2003, Dr. Rixe was appointed Professor of Medical Oncology at Pierre and Marie Curie University. He joined the Medicine Oncology Branch at the NCI as a staff clinician in 2008. At the University of Cincinnati as Professor of Medicine Dr. Rixe held the John and Gladys Strauss Chair in cancer research (2009). While at Cincinnati, he assumed the positions of Director of the Experimental Therapeutics Program and Deputy Director Division of Hematology/Oncology. From 2011-2012 he served a secondary appointment as Research Director of the UC Brain Tumor Center in the Department of Neurosurgery.
Olivier Rixe, M.D., Ph.D. Professor Section of Hematology/Oncology Director, Experimental Therapeutics Program Leader, Neuro-Oncology Program
Date: December 11, 2012 Time: Noon-1:00 PM Location: BC-140 Title of Presentation: "Is there a future role for antiangiogenics in oncology? The $440 Billion Question…"
About the Speaker: Dr. Rixe joined the Georgia Health Sciences University Cancer Center in April 2012 to lead the Experimental Therapeutics Program and the multi-disciplinary Neuro-Oncology group while holding a Professor of Medicine position. At GHSU Dr. Rixe conducts several clinical trials and translational studies, including Phase 1 studies for solid tumors, new therapeutic strategies in recurrent glioblastomas, and the evaluation of new biomarkers in brain tumors.
Objectives: The importance of VEGF in oncogenesis The mechanism of action of antiangiogenics The mechanism of drug resistance to antiangiogenics The current indication of antiangiogenics in oncology The perspectives for VEGF and non-VEGF angiogenic inhibitor in development